Method of treating coronary artery disease FGF-2
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorMartha Jo Whitehouse
Life of this patent
Estimating the term…
Abstract
The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
Claims28
A method for treating a human patient for coronary artery disease, comprising:
- administering a therapeutically effective amount of a recombinant fibroblast growth factor-2 (FGF-2) or an angiogenically active, terminally truncated fragment of said FGF-2 into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for said coronary artery disease, wherein said therapeutically effective amount is about 0.2 μg/kg to 48 μg/kg of patient weight;
- wherein said recombinant FGF-2 is human FGF-2 and has the amino acid sequence set forth in SEQ ID NO:
- 2 with a threonine residue substituted for the serine residue at position 112 of SEQ ID NO:
- 2 and a serine residue substituted for the proline residue at position 128 of SEQ ID NO:
- 2, and wherein said fragment of said FGF-2 comprises at least residue numbers 30-110 of SEQ ID NO:
- 2.
A method for treating a human patient for coronary artery disease, comprising:
- administering a single unit dose of a recombinant fibroblast growth factor-2 (FGF-2) or an angiogenically active, terminally truncated fragment of said FGF-2 into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose comprising from about 0.008 mg to 7.2 mg of said recombinant FGF-2 or said fragment of said FGF-2;
- wherein said recombinant FGF-2 is human FGF-2 and has the amino acid sequence set forth in SEQ ID NO:2 with a threonine residue substituted for the serine residue at position 112 of SEQ ID NO:2 and a serine residue substituted for the proline residue at position 128 of SEQ ID NO:2, and wherein said fragment of said FGF-2 comprises at least residue numbers 30-110 of SEQ ID NO:
- 2.
A method for treating a human patient for coronary artery disease, comprising:
- administering a therapeutically effective amount of a mutein of a recombinant fibroblast growth factor-2 (FGF-2) into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for said coronary artery disease, wherein said therapeutically effective amount is about 0.2 μg/kg to 48 μg/kg of patient weight;
- wherein said recombinant FGF-2 is human FGF-2 and has the amino acid sequence set forth in SEQ ID NO:
- 2 with a threonine residue substituted for the serine residue at position 112 of SEQ ID NO:
- 2 and a serine residue substituted for the proline residue at position 128 of the FGF-2 of SEQ ID NO:
- 2, and wherein the amino acid sequence of said mutein has at least 90% sequence identity to residues 1-146 of SEQ ID NO:
- 2, and wherein said mutein has angiogenic activity.
A method for treating a human patient for coronary artery disease, comprising:
- administering a single unit dose of a mutein of a recombinant fibroblast growth factor-2 (FGF-2) into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose comprising from about 0.008 mg to 7.2 mg of said mutein of said recombinant FGF-2;
- wherein said recombinant FGF-2 is human FGF-2 and has the amino acid sequence set forth in SEQ ID NO:
- 2 with a threonine residue substituted for the serine residue at position 112 of SEQ ID NO:
- 2 and a serine residue substituted for the proline residue at position 128 of SEQ ID NO:
- 2, and wherein the amino acid sequence of said mutein has at least 90% sequence identity to residues 1-146 of SEQ ID NO:
- 2, and wherein said mutein has angiogenic activity.
Dependencies are inferred from the claim text.